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OBJECTIVES This study sought to compare the effects of aggressive and conventional lipid lowering by two
different dosages of the same statin on early human atherosclerotic lesions using serial
noninvasive magnetic resonance imaging (MRI).
BACKGROUND Regression of atherosclerotic lesions by lipid-lowering therapy has been reported.
METHODS Using a double-blind design, newly diagnosed hypercholesterolemic patients (n  51) with
asymptomatic aortic and/or carotid atherosclerotic plaques were randomized to 20 mg/day (n
 29) or 80 mg/day (n  22) simvastatin. Mean follow-up was 18.1 months. A total of 93
aortic and 57 carotid plaques were detected and sequentially followed up by MRI every six
months after lipid-lowering initiation. The primary MRI end point was change in vessel wall
area (VWA) as a surrogate for atherosclerotic burden.
RESULTS Both statin doses reduced significantly total cholesterol (TC) and low-density lipoprotein
cholesterol (LDL-C) versus baseline (p 0.001). Total cholesterol decreased by 26% versus 33%
and LDL-C by 36% versus 46% in the conventional (20 mg) versus aggressive (80 mg) simvastatin
groups, respectively. Although the simvastatin 80-mg group had significantly higher baseline TC
and LDL-C levels, both groups reached similar absolute values after treatment. A significant
reduction in VWA was already observed by 12 months. No difference on vascular effects was
detected between the randomized doses. Post-hoc analysis showed that patients reaching mean
on-treatment LDL-C 100 mg/dl had larger decreases in plaque size.
CONCLUSIONS Effective and protracted lipid-lowering therapy with simvastatin is associated with a
significant regression of atherosclerotic lesions. No difference in vessel wall changes was seen
between high and conventional doses of simvastatin. Changes in vessel wall parameters are
more related to LDL-C reduction rather than to the dose of statin. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.0542005;46:106–12) © 2005 by the American College of Cardiology Foundation
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aipid-lowering by statins is the cornerstone of therapy for
rimary and secondary prevention of atherosclerotic disease.
clear reduction in the incidence of coronary events, both
mong patients with and without a previous history of
oronary heart disease (CHD), has been shown in several
arge randomized controlled studies with different statins.
he major mechanism of action of statins is the inhibition
f de novo cholesterol synthesis and increased expression of
ow-density lipoprotein cholesterol (LDL-C) receptors, re-
ulting in significant reductions of total cholesterol (TC)
nd LDL-C plasma levels. Whether this is the only mech-
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ork, New York. This study was supported by grants from the National Institutes of
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orti); The National Heart Foundation of Australia (Dr. Worthley); The French
ederation of Cardiology (Dr. Helft); and Merck and Co, Inc. Merck and Co. was
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esponsible for data acquisition, evaluation, and writing the manuscript without any
nterference from the funding sources.p
Manuscript received November 1, 2004; revised manuscript received March 18,
005, accepted March 22, 2005.nism of action responsible for the observed benefits re-
ains controversial.
Experimental (1) and clinical (2,3) evidence supports the
otion that statins stabilize high-risk (vulnerable) lesions by
educing the lipid content and inflammation of atheroscle-
otic plaque, thereby increasing the fibrous-muscular/lipid
issue ratio. It has been postulated that statins may reduce
therosclerotic burden, and by stabilizing the atherosclerotic
laques reduce the risk of plaque disruption. Plaque disrup-
ion is considered the leading mechanism responsible for the
hrombotic complications of atherosclerotic disease (4). On
he other hand, it also has been postulated that statins may
xert their clinical benefits via lipid-lowering independent
r pleiotropic mechanisms (5–7).
The availability of high-resolution imaging modalities
as significantly facilitated the possibility of performing in
ivo regression studies. Cross-sectional magnetic resonance
maging (MRI) has emerged as the most promising nonin-
asive technique for longitudinal in vivo studies of large
therosclerotic arteries (8). Its usefulness in studying plaque
rogression, stabilization, and even regression has been
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RI has been used to image human atherosclerotic lesions
n several vascular territories and its accuracy and reproduc-
bility in measuring atherosclerotic plaques has been re-
orted (9).
We have previously reported that despite an early hypo-
ipidemic effect, at least 1 year of treatment was needed to
etect significant changes in plaque size in clinically asymp-
omatic patients (10). Our preliminary results were recently
onfirmed in a case-control study reporting smaller plaque
ize, a smaller lipid core, and reduced lipid content in
atients treated with an aggressive lipid-altering regimen for
0 years (3). More importantly, prospective angiographic
tudies showed that simvastatin halted the progression of
tenotic coronary lesions (11) and the combination of
imvastatin and niacin has the potential to reduce the degree
f stenosis (12).
The purpose of this single-center, prospective, random-
zed trial was to investigate the long-term effect of lipid
owering by simvastatin on early atherosclerotic lesions in
umans and to compare the effects of aggressive versus
onventional therapy by means of two different dosages of
he same statin.
Abbreviations and Acronyms
CHD  coronary heart disease
HDL  high-density lipoprotein
IVUS  intravascular ultrasound
LA  lumen area
LDL-C  low-density lipoprotein cholesterol
MRI  magnetic resonance imaging
TC  total cholesterol
TE  echo time
TR  repetition time
TVA  total vessel area
VWA  vessel wall area
VWT  vessel wall thickness
able 1. Patient Characteristics According to the Treatment Gro
Range
Simvas
(n
ge (yrs) 41.4–82.9 62.6
MI (kg/m2) 18.8–34.8 26.5
C (mg/dl)* 193–356 257
DL-C (mg/dl)* 110–226 173
DL-C (mg/dl)* 26–126 57.0
G (mg/dl) 41–600 164
ortic lesions
Lumen (mm2) 251–1,092 464
TVA (mm2) 417–1,790 749
VWA (mm2) 145–884 285
arotid lesions
Lumen (mm2) 9.2–73.6 32
TVA (mm2) 43.0–151.6 79.1
VWA (mm2) 26.5–86.9 48.6
To convert values to millimoles per liter, multiply by 0.02586. †Significant differenc
iven as mean  SD.BMI  body mass index; HDL-C  high-density lipoprotein cholesterol; LDL-C  lo
total vessel area; VWA  vessel wall area.ETHODS
xperimental design. The study involved newly diagnosed
ypercholesterolemic (LDL 130 mg/dl and triglycerides
445 mg/dl) and clinically asymptomatic patients. Recruit-
ent started in March 1999, and the study was terminated
n March 2002.
Inclusion criteria were based on the pre-existence of
therosclerotic plaques (thoracic aortic wall 4.0 mm
nd/or carotid wall 2.0 mm thick) detected by carotid
-mode ultrasound, echocardiography, or MRI. Serial MRI
tudies of the thoracic aorta and carotid arteries were
erformed at baseline and every 6 months after therapy
nitiation. This study design allowed each patient to serve as
is or her own control, hence offering the opportunity to
tudy progression or regression of the same (or individual)
therosclerotic lesions using MRI.
Exclusion criteria were heart failure, renal or hepatic
isease, significant carotid disease, or a clinically significant
edical or surgical event within 3 months before study
ntry. Of 110 patients screened, 51 patients fulfilled the
nclusion criteria and were enrolled after providing written
onsent. Patients were randomized in a double-blind fash-
on to conventional (simvastatin 20 mg) or aggressive
simvastatin 80 mg) lipid-lowering interventions.
The patient characteristics are summarized in Table 1.
linical follow-up was done at 6, 12, 24, and 48 weeks and
lood samples were drawn at baseline, 6, 12, 24, 48, 72, and
6 weeks to determine lipid levels and safety parameters.
he local institutional review board approved the protocol.
RI protocol. Imaging was performed on a 1.5-T whole-
ody MRI system (Signa CV/i, GE Medical Systems, Mil-
aukee, Wisconsin; 40 mT/m; SR150) as previously described
10,13). In brief, four-element phased-array coils were used for
arotid and aortic imaging. After localization with a fast-
radient-echo sequence, all images were obtained with a
ouble-inversion recovery (i.e., black-blood) fast-spin-echo
80 mg
)
Simvastatin 20 mg
(n  29) p Value†
6 62.3  10.0 NS
2 25.1  3.7 NS
241  39 .0089
154  31 .0005
.5 55.6  20.7 NS
163  116 NS
0 425  149 NS
6 744  267 NS
319  176 NS
33  14 NS
.2 80.4  26.1 NS
.6 47.8  16.4 NS
een the treatment groups (20 mg vs. 80 mg) are tested by unpaired t test. Data areup
tatin
 22
 7.
 3.
 38
 33
 19
 84
 17
 23
 80
 11
 20
 12
es betww-density lipoprotein cholesterol; TC  total cholesterol; TG  triglycerides; TVA
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Lipid Lowering and Human Atherosclerotic Lesions July 5, 2005:106–12equence with electrocardiographic gating during free breath-
ng (14). Twenty-five to 30 transverse images centered at the
arotid bifurcation were taken.
Imaging parameters were: repetition time (TR), 2 R-R
ntervals; echo time (TE), 12/45 ms (proton density-
eighted/T2-weighted); field of view, 12 cm; slice thick-
ess, 3 mm; no interslice gap, acquisition matrix, 256 
56; 512 zero filling; no phase wrap; number of signal
veraged 1/2 (proton density–weighted/T2-weighted);
cho-train length, 32; receiver bandwidth, 64 kHz. A
hemical shift suppression pulse was used to suppress the
ignal from perivascular fat. For the aorta, 25 to 30
ransverse images from the origin of the left subclavian
rtery to the level of the diaphragm were obtained. For the
ortic arch, 10 to 12 cross-sectional oblique images (per-
endicular to the vessel wall) were acquired. The imaging
arameters were similar as for carotid imaging, except:
0-cm field of view and 5-mm slice thickness.
The in-plane resolution was 780  780 m for the aorta
nd 469  469 m for the carotid artery. The total
xamination lasted 60 to 90 minutes.
orphometric analysis. The MR images were transferred
o a Macintosh computer for further planimetric analysis.
pecial attention was given to match images of the same
atient at different follow-up time points, using several
natomic landmarks (i.e., carotid bifurcation, top of the
ortic arch, origin of the coronaries, pulmonary artery
ifurcation, and pulmonary veins) as previously described
9,14). To minimize sub-millimeter errors in the matching
f the images at different time points, at least five contigu-
us MR images per plaque were analyzed and their average
as considered for statistical analysis. Computer-assisted
orphometric analysis of cross-sectional MR images was
sed to measure vessel wall dimensions by semiautomatic
racing (Image Pro-Plus, Media Cybernetics, Carlsbad,
alifornia). The tracing tool works by following an edge
i.e., boundary) of significant contrast. Lumen area (LA);
otal vascular area (TVA); minimal, maximal, and mean
essel wall thickness (VWT); and vessel wall area (VWA 
VA  LA) were calculated. The measurements were
erformed blinded to the patient’s identity and image order.
he reproducibility of the VWA measurement has been
reviously reported (9,10,14). We reported an image-
pecific error (standard deviation between matched images)
f 6 mm2 for aortic and 2 mm2 for carotid images. If the
verage values of five contiguous images were considered,
he error was reduced at 4.5 mm2 for aortic and 1.5 mm2 for
arotid images. This corresponds to an error of 2.6% for
ortic and 3.5% for carotid plaques. Based on our reproduc-
bility data, we calculated that changes in plaque size of
ore than 5.2% for aortic and more than 7% for carotid
esions are likely to be accurately measured by MRI (10).
The effects of the lipid-lowering intervention on athero-
clerotic lesions were assessed as changes in vessel dimen-
ions versus baseline. A direct effect of simvastatin on
ormal vessel wall (no plaque visually detectable, maximal aWT 3 mm for aortic and 2 mm for carotid segments)
as been previously ruled out by analyzing 28 non-
therosclerotic arterial segments (17 aortic and 11 carotid
egments) after 12 months of treatment (10). The difference
n VWA was 2.4% (p  0.8) for aortic and 3.9% (p  0.3)
or carotid segments.
tatistical analysis. Data are presented as mean  SD.
tatistical analysis was performed using analysis of variance
or repeated measures or Student’s t test (StatView 4.1,
002, ABACUS Inc., Cary, North Carolina). A value of p
0.05 was considered significant.
ESULTS
aseline characteristics. Demographic characteristics,
lasma lipid levels, and vessel wall dimensions at baseline are
eported in Table 1. The average age of the patients was 62
ears, with a mean body mass index of 25.7 kg/m2. Fifty-one
atients were included in the study; 40% female patients, 31%
ypertensive patients, 33% previous smokers, 30% current
mokers, and 19% with diabetes. All patients were clinically
symptomatic. A total of 93 aortic and 57 carotid plaques were
dentified and followed up by MRI. Twenty-nine patients were
ssigned randomly to 20 mg/day simvastatin (conventional
reatment group) and 22 patients to 80 mg/day simvastatin
aggressive treatment group). No significant differences were
bserved between the treatment groups, with the exception of
C and LDL-C, which were significantly higher in the
atients assigned to simvastatin 80 mg.
The mean follow-up was 18.1  6.3 months. An MRI
ollow-up was performed in 40 patients at 12 months, in 33
atients at 18 months, and in 20 patients at 24 months.
One patient was lost to follow-up during the first 6
onths: a 52-year-old man with no previous episode of
ngina died suddenly during exercise 3 weeks after starting
n the conventional treatment group.
ffect on plasma lipid levels. As expected, simvastatin
herapy was associated with a significant reduction in both
C and LDL-C (Fig. 1). For the conventional treatment
roup, receiving simvastatin 20 mg, the reduction was 25%
or TC and 36% for LDL-C. The aggressive treatment
roup, receiving simvastatin 80 mg, showed an additional
% reduction in TC, corresponding to a total decrease of
2% versus baseline values. For LDL-C the additional
eduction was 10%, corresponding to a total reduction of
6% versus baseline. Simvastatin 80 mg induced a signifi-
antly higher percent decrease in TC and LDL-C than
imvastatin 20 mg (Fig. 1).
The maximal hypolipidemic effect was already achieved
ithin the first 6 weeks of treatment, and a further decrease
as not shown throughout the duration of the study.
lthough the group of patients assigned randomly to
imvastatin 80 mg had significantly higher baseline levels of
C and LDL-C, both treatment groups reached similar
bsolute values after treatment (Fig. 1). After treatment, the
verage TC was 181 mg/dl for the conventionally and 175
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July 5, 2005:106–12 Lipid Lowering and Human Atherosclerotic Lesionsg/dl for the aggressively treated group, respectively. Mean
evels of LDL-C on-treatment were 98 and 93 mg/dl,
espectively.
ffect on plaque size. The effects of both lipid-lowering
reatments on carotid and aortic atherosclerotic lesions
hroughout the study are shown in Figure 2. Overall, statin
dministration was associated with a significant decrease in
WA over time (analysis of variance p  0.001) for both
ortic and carotid atherosclerotic lesions. At least 12 month
f treatment was required before any statistically significant
hange in VWA could be detected. Aortic VWA decreased
y 10% at 12 months and by 15% at 24 months. Carotid
WA decreased by 14% and 18% at 12 and 24 months,
espectively. Similar trends were seen for change in maximal
WT, confirming that the changes take place in the
hickened areas of the vascular wall, because normal wall did
ot show any change. The decrease in VWT was 9% at 12
onths and 15% at 24 months in aortic lesions. In carotid
esions, VWT decreased by 10% at 12 months and by 17%
t 24 months. Aortic lumen increased by 5% and 6% at 18
nd 24 months, respectively. Carotid artery lumen increased
y 4% and 5%, respectively. No change in lumen size was
etected at 6 and 12 months. Similar trends in change over
ime were seen for both statin dosages. In fact, no difference
as seen between the two treatments for any of the vascular
easurements.
A representative MRI follow-up at the level of the carotid
ifurcation in the same patient at baseline and at 24 months
n statin is shown in Figure 3. The optimal matching of the
mages can be appreciated by the similar pattern of the vein
owing into the internal jugular vein.
elationship between changes in lipid levels and
laque. No direct relationship was observed between the
wo regimens at either the systemic or the vascular level.
igure 1. Bar graph showing the effect of statin treatment on plasma low-d
uring treatment and the pre-treatment value were used to calculate the ch
f treatment (A) and for the percent change in LDL-C (B). The line descr
ith baseline was seen for both 20-mg and 80-mg simvastatin doses (A). Th
n LDL-C (B). Because of significantly higher baseline LDL-C values inhe two doses of simvastatin had similar changes on plaque larameters. When vascular changes were correlated with
ffect on systemic lipid levels, independently of the statin
ose, no direct relationship was observed between LDL
owering and absolute changes in plaque characteristics.
nterestingly, LDL lowering did have a significant impact
n the time required for the changes to occur.
The post-hoc analysis of the vascular effects according to
he median split of the lipid-lowering effect, independently
f the treatment group assignment, showed that the group
hat reached lower LDL-C levels had the faster decrease in
WA (slope r  0.62 vs. r  0.53). Accordingly, the
roup with the larger percent decrease in LDL-C had a
arger decrease in VWA (slope r  0.58 vs. r  0.57).
More interesting were the observations when the effects
f therapy were analyzed based on the efficacy in achieving
he National Cholesterol Education Program (NCEP) goals
f LDL-C plasma levels of 100 mg/dl independent of the
reatment received. Patients that reached an LDL-C 100
g/dl showed a larger decrease in plaque size compared
ith those that did not achieve this cholesterol goal.
atients that reached LDL-C 100 mg/dl had a 17%
eduction in aortic VWA, versus a 12% in the group with
n-treatment levels of100 mg/dl LDL-C. This difference
as statistically significant (p  0.027). Similar trends were
een for lesions in the carotid arteries (Fig. 4). An average
WA decrease of 16.5% in patients with LDL-C 100
g/dl versus a 12% decrease in patients with LDL-C 100
g/dl was seen (p  0.36).
ISCUSSION
his long-term in-vivo human study shows that effective
nd protracted lipid-lowering therapy by simvastatin is
ssociated with a significant regression of atherosclerotic
y lipoprotein. Mean value of low-density lipoprotein cholesterol (LDL-C)
. The bars describe the number of patients for a mean LDL-C at the end
he distribution of the data. A significant decrease in LDL-C as compared
mg simvastatin group is associated with a significantly greater 10% decline
igh-dose group, both groups ended in similar absolute values.ensit
anges
ibes tesions (10,13). Interestingly, in this cohort of asymptomatic
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Lipid Lowering and Human Atherosclerotic Lesions July 5, 2005:106–12atients presenting with untreated hypercholesterolemia
nd atherosclerotic lesions of the aorta or carotid artery,
imilar regression was noticed in both vascular territories. In
ddition, the group of patients with a more aggressive
ypolipidemic effect achieved an earlier and more marked
eduction of the asymptomatic atherosclerotic lesions.
ther investigators using combined surface and transesoph-
geal MRI in the thoracic aorta have confirmed this
bservation (15).
Recently, Jensen et al. (16) reported similar results in the
oronary circulation in patients with hemodynamically non-
ignificant coronary stenoses (50% stenoses) after 15
onths of simvastatin treatment. This intravascular ultra-
ound (IVUS) study showed that statin treatment induces
oronary vessel shrinkage without affecting the lumen dur-
ng the first year of treatment, which confirms our findings
hat statin treatment may reverse some of the compensatory
nlargement seen in early atherosclerotic lesions (13). More
ecently, Nissen et al. (17) showed that aggressive lipid-
owering therapy by atorvastatin reduces lesion progression
n patients with more severe coronary disease and partial
tatin pretreatment. These findings confirm our hypothesis
hat atherosclerotic plaque regression is possible by lipid-
igure 2. Effect of statin treatment on plaque size. Bar graphs showing
ata on vessel wall area at baseline, 6, 12, 18, and 24 months for aorta
upper panel) and carotid artery (lower panel) for the 20 patients who
eached the 24-month follow-up. Data are displayed according to the statin
ose: simvastatin 20 mg (white bars) and 80 mg (black bars). Data are
iven as mean  SEM.owering interventions. These effective interventions, by bemoving the intravascular lipid deposition, would lead not
nly to plaque reduction but also to its stabilization. These
bservations reinforce our hypothesis that early lipid-
owering treatment before the atherosclerotic disease
rogresses to clinically manifest lesions would render faster
nd more efficient benefits. Further efforts should be made
o provide early detection of atherosclerosis, better patient
isk stratification, and clearer definition of the optimal time
oint at which to intervene with the most adequate treat-
ent. In fact, little is known about the natural history of
therosclerosis and the rate of progression of stable disease,
rucial information for better interpretation of the available
esults of different interventions in atherosclerosis. The
vailability of the new non-invasive imaging modalities may
ake a significant impact on these unanswered questions.
Surprisingly, we found similar trends on plaque size effect
n patients treated with 20 mg and 80 mg simvastatin,
ithout any substantial difference between the groups. A
ossible explanation for these unexpected results lies in the
ifference between the baseline lipid levels for the two
roups. In fact, patients assigned to the aggressive interven-
ion had significantly higher LDL-C levels at baseline.
lthough the 80-mg dose had a higher relative hypolipi-
emic effect than the 20-mg dose (LDL-C reduction of
6% vs. 36%, p  0.01, Fig. 1B), both groups reached
imilar lipid levels after treatment (Fig. 1A).
The results of our study support the hypothesis that the
bserved clinical benefits of statins seem to be mediated
redominantly via their hypolipidemic effect. In fact, the
tratification of the results in a post-hoc analysis, according
o the LDL-C, showed that patients who reached an
DL-C 100 mg/dl (2.6 mmol/l) had greater regression
f atherosclerotic lesions (Fig. 4). These data support the
DL-C goal defined by the NCEP Adult Treatment Panel
ATP)-III guidelines for secondary prophylaxis in CHD
nd CHD risk equivalents and should further stimulate the
edical community to increase the effort toward this goal.
ur data support the increasing consensus that “lower is
etter” and raise the question of whether stricter new
uidelines, with lower lipid levels, are required to further
educe the socioeconomic impact of cardiovascular diseases.
Interestingly, despite the early maximal hypolipidemic
ffect (obtained after 6 weeks of treatment), at least 12
onths of treatment is needed before detecting significant
hanges in lesion characteristics. In the recently published
eart Protection Study, a significant benefit of simvastatin
n a dose of 40 mg was shown independently of the baseline
ipid levels (18). Similar to previous prevention trials, the
linical benefit of statin treatment became evident only after
2 months of treatment (18). The changes in plaque size
hown in our study are potentially expressive of the trans-
ormation in plaque composition leading to a stabilization of
he lesion. This hypothesis is supported by several experi-
ental and observational studies showing lipid depletion in
therosclerotic lesions after prolonged lipid lowering either
y statin or by diet (1,9,12,19). An important question that
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July 5, 2005:106–12 Lipid Lowering and Human Atherosclerotic Lesionsould not be addressed by this study is whether the observed
laque regression could be achieved at an earlier time in
atients with more advanced atherosclerotic lesions.
The degree of LDL-C reduction seems a good predictor for
laque regression. Three recently published studies investi-
ated the effects of aggressive versus conventional lipid-
owering interventions in a population with more advanced
therosclerosis. The IVUS-based Reversal of Atherosclerosis
ith Aggressive Lipid Lowering (REVERSAL) trial (17)
stablished the benefits of a more aggressive hypolipidemic
ntervention in coronary lesions, whereas the Pravastatin or
torvastatin Evaluation and Infection Therapy (PROVE-IT)
rial (20), an event-based study in patients with acute coronary
yndromes, showed a significant reduction in the number of
ardiovascular events by an aggressive lipid-lowering strategy
ompared with a conventional approach. Surprisingly, disap-
ointing results from the Phase Z of the A to Z trial (21) were
ore recently reported. This large, multicenter, double-blind
tudy in 4,497 acute coronary syndrome patients did not
onfirm the benefit of an early initiation of an aggressive
igure 3. Representative cross-sectional magnetic resonance image of the
egression at the level of the right carotid artery bifurcation. ICA  inter
igure 4. Effect of lipid lowering on plaque size according to the 100 mg/d
VWA) are displayed according to the goal of 100 mg/dl (2.6 mmol/l). O
ho reached the goal had a significantly higher regression in aortic lesions (left pa
f the last available magnetic resonance imaging examination and the baselineimvastatin regiment and resulted only in a favorable trend
oward reduction of major cardiovascular events.
The hypolipidemic effect of statins and lipid removal
rom the atherosclerotic lesions are probably the major
echanisms responsible for the clinical benefits observed in
hese trials. A possible explanation for the different results
etween our study and the REVERSAL study rests in the
ifferent patient characteristics and the fact that we used
wo dosages of the same statin, whereas the REVERSAL
tudy used two different statins. This observation, added to
he contrasting results of the PROVE-IT trial (20) and
hase Z of the A to Z trial (21), also raises concerns
egarding whether all of the statins are equal. Our goal was
o study early-stage atherosclerotic lesions. Therefore, we
elected a cohort of asymptomatic and newly diagnosed
ypercholesterolemic, statin-naive patients, who are more
ikely to have smaller and less fibrotic lesions.
Further studies should be performed to define the ideal
cholesterol level threshold” and the real benefits of
ggressive versus conventional lipid-lowering therapy
patient at baseline and at 24 months of statin treatment showing plaque
rotid artery; IJV  internal jugular vein.
density lipoprotein cholesterol (LDL-C) goal. Changes in vessel wall area
tment, LDL-C 100 mg/dl is associated with larger regression. Patientsl low-
n treanel). A similar trend was seen for carotid lesions (right panel). The values
value were used to calculate percent changes in VWA.
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Incremental Decrease in End Points through Aggressive
ipid Lowering [IDEAL], Treating to New Target
TNT], Study of Effectiveness of Additional Reductions
n Cholesterol and Homocysteine [SEARCH]) will
robably provide an answer for this dilemma. The po-
ential of other lipid-modifying therapies as well as
pproaches aimed at modifying plaque composition
hould be further elucidated. In 1990, Badimon et al. (22)
escribed the anti-atherogenic effects of the administration of
omologous high-density lipoprotein (HDL) in an experi-
ental model of atherosclerosis. Spieker et al. (23) recently
eported rapid normalization of endothelium-dependent vaso-
ilation by increasing nitric oxide bioavailability after infusion
f reconstituted HDL infusion in hyperlipidemic patients.
egression of human atherosclerotic lesions has been shown by
VUS after five weekly infusions of recombinant apolipopro-
ein A-I Milano (24). These observations raise the question of
hether a combination of an LDL-lowering and HDL-raising
pproach could be the most effective intervention for regressing
therosclerotic lesions. The potential effectiveness of combin-
ng two interventions with different mechanisms of action has
een recently investigated by our group at the preclinical level
y combining a statin with a selective peroxisome proliferator-
ctivated receptor-gamma agonist (25).
In conclusion, effective and protracted lipid-lowering
herapy by simvastatin is associated with a significant
egression of atherosclerotic lesions. Our data strongly
upport the efficacy and potential clinical benefits of an
ffective and aggressive lipid-lowering intervention on ath-
rosclerotic disease. Plaque regression was more related to
he degree of LDL-C reduction rather than to the dose of
tatin, because no difference between high- and moderate-
ose simvastatin was detected.
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